<DOC>
	<DOCNO>NCT02504541</DOCNO>
	<brief_summary>Evaluation safety concentration control testosterone enanthate QuickShot Testosterone regimen administer subcutaneously week adult male hypogonadism .</brief_summary>
	<brief_title>Subcutaneous Testosterone Enanthate Safety Adult Men Diagnosed With Hypogonadism ( STEADY )</brief_title>
	<detailed_description>Safety assessment , include laboratory assessment , adverse event injection site assessment , conduct patient schedule interval Treatment Titration Period .</detailed_description>
	<mesh_term>Hypogonadism</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<criteria>Adult men ≥18 ≤75 year age document history hypogonadism Total testosterone level &lt; 300 ng/dL two qualification visit Patients good general health Allergy sesame testosterone product BMI ≥ 40 kg/m2 Hematocrit ≥ 52 % History current evidence breast prostate cancer Elevated prostatespecific antigen ( PSA ) age . Abnormal digital rectal examination ( DRE ) Unstable psychiatric illness Obstructive uropathy prostatic origin Poorly control diabetes Congestive heart failure Within 6 month screen , myocardial infarction ( MI ) , unstable angina lead hospitalization , percutaneous coronary intervention , coronary artery bypass graft , uncontrolled cardiac arrhythmia , stroke transient ischemia attack , carotid revascularization , endovascular procedure , surgical intervention peripheral vascular disease . History current treatment thromboembolic disease . Use adrenocorticotropic hormone ( ACTH ) oral/depot corticosteroid within 6 week screen . History severe , untreated sleep apnea Subjects clinically significant medical condition , opinion investigator , would make subject unsuitable candidate enrollment study Positive serology HIV , hepatitis B hepatitis C Current evidence drug alcohol abuse . Skin condition injection site could confound injection site assessment . Administration investigational compound within one month screen 5 halflives investigational compound , whichever long ) . Use estrogen , gonadotropinreleasing hormone ( GnRH ) growth hormone within 12 month screen . Use androgen ( DHEA ) , anabolic steroid , sex hormone ) substances/supplements know affect pharmacokinetics ( PK ) testosterone enanthate Considered schedule surgical dental procedure associate blood loss ≥500 mL study . Donation plasma blood within 56 day screen history donation &gt; 50 mL blood plasma within 3 month screen . Donation plasma blood study</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Hypogonadism</keyword>
	<keyword>Testosterone enanthate</keyword>
</DOC>